Stock Monitor: Caladrius Biosciences Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Mesoblast Ltd (NASDAQ: MESO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MESO as the Company's latest news hit the wire. On April 17, 2018, the Company announced an update on the Phase-3 DREAM-HF trial and Phase-2b clinical trials of the Company's proprietary allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in patients with moderate-to-severe and end-stage advanced chronic heart failure (CHF), respectively. Register today and get access to over 1000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Caladrius Biosciences, Inc. (NASDAQ: CLBS), which also belongs to the Healthcare sector as the Company Mesoblast. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Mesoblast most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Positive clinical signals have been previously published in Phase-2 trials of Mesoblast's MPC therapy in advanced and end-stage heart failure supporting a common underlying mechanism of action (MOA).
Phase-3 DREAM-HF Trial Targeting Patients with Moderate-to-Advanced Chronic Heart Failure
The objectives of the Phase-3 trial are to evaluate the ability of MPC-150-IM to reduce the primary endpoint of recurrent non-fatal heart failure-related major adverse cardiac events (HF-MACE) in patients with left ventricular dysfunction, as well as delay or prevent disease progression to end-stage HF and terminal cardiac events (TCE), defined as death, left ventricular assist device (LVAD) implantation, or cardiac transplant. In April 2017, an interim futility analysis of the recurrent non-fatal HF-MACE primary efficacy endpoint in the DREAM-HF's first 270 patients was reported successful. The trial met the pre-specified threshold for continuation.
In April 2018, the Data Monitoring Committee (DMC) for the Phase-3 trial undertook a scheduled review of available data from 465 randomized patients. The DMC recommended continuation of the trial without modification. Enrollment of this Phase-3 trial is expected to be completed by the end of 2018.
Phase-2b Trial Targeting End-State Heart Failure Patients with LVAD
In December 2017, based on prior Phase-2 trial results which suggested that Mesoblast's MPCs improved native heart function, prolonged time to re-hospitalization and improved early survival in patients with an LVAD, the United States Food and Drug Administration (FDA) granted Mesoblast Regenerative Medicine Advanced Therapy (RMAT) designation for its MPC therapy in the treatment of heart failure patients with left ventricular systolic dysfunction and an LVAD. The RMAT designation under the 21st Century Cures Act aims to expedite the development of regenerative medicine therapies intended for the treatment of serious diseases and life-threatening conditions, and also offers eligibility for priority review.
A 159-patient trial, funded by the National Institutes of Health (NIH) and the Canadian Institute of Health Research, and evaluating Mesoblast's investigational MPC cells as add-on therapy to LVADs has completed enrollment. The objectives of this Phase-2b trial are to confirm and extend the prior Phase-2 results. The Company is pursuing a potential accelerated entry pathway for MPC-150-IM into the cardiovascular market that may be provided by RMAT designation.
About Chronic Heart Failure
Heart failure (HF), often referred to as CHF, is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling. Common causes of heart failure include coronary artery disease including a previous myocardial infarction (heart attack), high blood pressure, atrial fibrillation, valvular heart disease, excess alcohol use, infection, and cardiomyopathy of an unknown cause.
MPC-150-IM is a tier 1 product candidate which consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function.
About Mesoblast Ltd
Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast is a world leader in innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates.
Stock Performance Snapshot
April 19, 2018 - At Thursday's closing bell, Mesoblast's stock declined 1.84%, ending the trading session at $5.88.
Volume traded for the day: 22.89 thousand shares.
Stock performance for year-to-date - up 0.68%
After yesterday's close, Mesoblast's market cap was at $580.12 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.